



Melody Smith, MD, MS

Assistant Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)

Medicine - Blood & Marrow Transplantation

CLINICAL OFFICE (PRIMARY)

- **BMT Division**

300 Pasteur Dr H0101

MC 5623

Stanford, CA 94305

Tel (650) 723-0822 Fax (650) 725-8950

Bio

BIO

Dr. Smith is a board-certified, fellowship-trained medical oncologist and hematologist. She is an Assistant Professor in the Department of Medicine within the Division of Blood & Marrow Transplantation and Cellular Therapy.

She is also a physician-scientist who conducts extensive research. As a medical student, she completed a fellowship at the National Institutes of Health (NIH) in the Clinical Research Training (now, the Medical Research Scholars) Program. Subsequently, after her clinical fellowship, she was a post-doctoral researcher at Memorial Sloan Kettering Cancer Center. Her lab's research focuses on studying the biology of chimeric antigen receptor (CAR) T cells to improve the therapy's efficacy and safety (1) by examining donor (Nature Medicine, 2017) and off-the-shelf CAR T cells in mouse models and (2) by investigating how the intestinal microbiome affects CAR T cell response (Nature Medicine, 2022).

Dr. Smith presents her research findings at regional, national, and international conferences. Additionally, she has co-authored articles on topics in cancer immunology, including cancer immunotherapy, stem cell transplantation, and CAR T cell therapy. Her work has been published in journals such as Nature, Nature Immunology, Nature Medicine, Blood, and Transplantation and Cellular Therapy. She serves as a peer reviewer for publications like NEJM Evidence, Science Advances, Blood, Cancer Cell, and Molecular Therapy. She has also contributed chapters to books, including Pocket Oncology, Current Concepts and Controversies in Hematopoietic Cell Transplantation, and Advanced Concepts in Human Immunology: Prospects for Disease Control.

She has received numerous honors; the American Society of Hematology, the American Society for Clinical Investigation, the Society for Immunotherapy of Cancer, the European Society for Blood and Marrow Transplantation, and several other professional organizations have recognized her achievements as a clinician, researcher, and scholar.

CLINICAL FOCUS

- Hematology

- Lymphoma
- Adoptive Cellular Immunotherapy
- Bone Marrow Transplantation

ACADEMIC APPOINTMENTS

- Assistant Professor - University Medical Line, Medicine - Blood & Marrow Transplantation
- Member, Bio-X
- Member, Stanford Cancer Institute

ADMINISTRATIVE APPOINTMENTS

- Assistant Professor, Division of Blood & Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, (2021- present)

HONORS AND AWARDS

- Young Physician-Scientist Award, American Society for Clinical Investigation
- WIN Leadership Institute, Society for Immunotherapy of Cancer
- Best Basic Science Abstract, European Society for Blood and Marrow Transplantation
- Abstract Achievement Award, American Society of Hematology
- Translational Research Training in Hematology, American Society of Hematology & European Hematology Association
- Clinical Research Training Course, American Society for Transplantation and Cellular Therapy
- ASH HIP Award (formerly MMSAP), American Society of Hematology (ASH)

PROFESSIONAL EDUCATION

- Board Certification, American Board of Internal Medicine , Medical Oncology
- Board Certification, American Board of Internal Medicine , Hematology
- Board Certification, American Board of Internal Medicine , Internal Medicine
- Fellowship, Memorial Sloan Kettering Cancer Center , Medical Oncology and Hematology
- Residency, University of Texas Southwestern Medical School , Internal Medicine
- Internship, University of Texas Southwestern Medical School , Internal Medicine
- Medical Education, University of Texas Southwestern Medical School , MD with Distinction in Research

LINKS

- Lab Site: <https://smith-lab.stanford.edu/>

Research & Scholarship

CLINICAL TRIALS

- Expanded Access Protocol (EAP) for Nonconforming (NC) Afi-cel, Recruiting
- Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel, Not Recruiting

Teaching

STANFORD ADVISEES

Postdoctoral Faculty Sponsor

Zhenyu Dai, Christopher Price, Maria Solsona Gaya, Jiayi Xie

GRADUATE AND FELLOWSHIP PROGRAM AFFILIATIONS

- Cancer Biology (Phd Program)
- Immunology (Phd Program)

Publications

PUBLICATIONS

- **Allogeneic hematopoietic cell transplantation for acute leukemia patients not in complete remission**
Elias, S., Brown, S., Eagini, O., Walji, M., Homsy, S., Velayati, A., Devlin, S., Ponce, D., Kennedy, V., Bharadwaj, S., Shiraz, P., Jakubowski, A. A., Papadopoulos, et al
LIPPINCOTT WILLIAMS & WILKINS.2025
- **Antibiotic Use: Impact on the Microbiome and Cellular Therapy Outcomes.** *Blood advances*
Darwin, A., Xie, J., Smith, M.
2025
- **The intestinal microbiota and cellular therapy: implications for impact and mechanisms.** *Blood*
Xie, J., Smith, M.
2024
- **Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy.** *Nature medicine*
Smith, M., Dai, A., Ghilardi, G., Amelsberg, K. V., Devlin, S. M., Pajarillo, R., Slingerland, J. B., Beghi, S., Herrera, P. S., Giardina, P., Clurman, A., Dwomoh, E., Armijo, et al
2022
- **Donor CD19 CART cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity** *NATURE MEDICINE*
Ghosh, A., Smith, M., James, S. E., Davila, M. L., Velardi, E., Argyropoulos, K. V., Gunset, G., Perna, F., Kreines, F. M., Levy, E. R., Lieberman, S., Jay, H. V., Tuckett, et al
2017; 23 (2): 242-249
- **American Society of Hematology: Building a Comprehensive Minority Recruitment and Retention Professional Program.** *Blood advances*
Rollins, M. R., Warsame, R., Smith, M., Molina, A., Rouce, R. H., Avalos, B. R., Johnson, C. S., Lopez, J. A., Thompson, A. A., Fanning, L., Frustace, P., Roche, K., van Havre, et al
2026
- **AI Guided Parenteral Nutrition Therapy After Hematopoietic Stem Cell Transplantation.** *NPJ digital medicine*
El Ariss, A. B., Phongpreecha, T., Ghanem, M., Kimari, M., James, T., Freche, E., Kerner, J. A., Gaudillière, B., Angst, M. S., Gaskari, S., Stevenson, D. K., Smith, M., Aghaepour, et al
2026
- **Post CAR-T Measurable Residual Disease Monitoring in Mantle Cell Lymphoma Enables Early Detection of Disease Relapse.** *American journal of hematology*
Ananth, S., Agarwal, N., Sahaf, B., Jacob, A., Lee, L. W., Simmons, H., Kirsch, I., Bharadwaj, S., Weng, W. K., Smith, M., Dahiya, S., Miklos, D., Frank, et al
2026
- **Respiratory Viral Infections Following CD19 CAR T-Cell Therapy.** *Journal of medical virology*
Weiss, J. J., Messina, J., Saullo, J., Li, Y., Andermann, T. M., Smith, M., Schrum, D., Eberwein, E., Kennedy, E., Rowe-Nichols, K., Kelsey, C., Choi, T., McKinney, et al
2026; 98 (5): e70941
- **Brexu-cel plus dasatinib: Safety and feasibility of dasatinib pulses after brexucabtagene autoleucel to modulate CAR T cell activity in relapsed/refractory B cell acute lymphoblastic leukemia**
Jeyakumar, N., Shiraz, P., Weber, E., Kanegai, A., Wagner, C., Ramakrishnan, A., Sahaf, B., Frank, M., Dahiya, S., Smith, M., Sidana, S., Mackall, C., Miklos, et al
AMER ASSOC CANCER RESEARCH.2026
- **Dynamics of BCMA expression in patients with relapsed/refractory multiple myeloma receiving BCMA-directed CAR-T therapy.** *Blood cancer journal*

- Rana, M. S., Fernandez-Pol, S., Jensen, A., Hovanky, V., Velayati, A., Oak, J. S., Silva, O., Ames, E., Muffly, L. S., Sahaf, B., Arai, S., Kennedy, V. E., Bharadwaj, et al
2026
- **Superior Chronic GVHD-Free Survival with Post-Transplant Cyclophosphamide Relative to Tacrolimus/Methotrexate in Myeloablative HLA-Matched Allogeneic Hematopoietic Cell Transplantation.** *Transplantation and cellular therapy*
Molina, A., Bubb, Q. R., Srinagesh, H. K., Yee, R., Arai, S., Bharadwaj, S., Dahiya, S., Elmariah, H., Frank, M., Hosoya, H., Johnston, L., Meyer, E., Mikkilineni, et al
2026
 - **Early Steroid and Anakinra Use to Manage Axicabtagene Ciloleucl Toxicity Reduces the Total Duration of CRS and ICANS.** *Blood advances*
Wang, W. L., Lee, D., Cheung, E., Jensen, A., Rana, M. S., Goyal, A., Hamilton, M. P., Ghalehsari, N., Latchford, T., Scott, B. J., Mallampet, J., Heng, E., Khan, et al
2026
 - **Patient Characteristics, Toxicity, and Response after Real World Administration of Obecabtagene Autoleucl and Brexucabtagene Autoleucl for Relapsed Acute Lymphoblastic Leukemia: A Rocca Analysis**
Molina, A., Shiraz, P., Kanegai, A., Fraser, A., Kordek, D., Wagner, C., Danley, L., Ramakrishnan, A., Daghigh, H., Huang, Y., Dhapola, G., Siddiqui, A., Arai, et al
ELSEVIER SCIENCE INC.2026: S27
 - **Impact of Social Determinants of Health on Access to CAR-T Therapy and Outcomes in Multiple Myeloma Patients**
Rana, M., Kaveh, N., Jensen, A., Kennedy, V. E., Weng, W., Smith, M., Shiraz, P., Jandir, N., Latchford, T. M., Frank, M., Bharadwaj, S., Dahiya, S., Miklos, et al
ELSEVIER SCIENCE INC.2026
 - **Characterization and Outcomes of Switching Tacrolimus to Sirolimus in Patients with Transplant-Associated Thrombotic Microangiopathy**
Kennedy, V. E., Lauer, M., Shiraz, P., Arai, S., Johnston, L., Bharadwaj, S., Dahiya, S., Elmariah, H., Frank, M., Lowsky, R., Meyer, E. H., Mikkilineni, L., Muffly, et al
ELSEVIER SCIENCE INC.2026
 - **AI-Quantified Patient Frailty Predicts Clinical Response to CAR-T**
Smith, C. J., Fettahoglu, A., Johnston, A., Smith, B. R., Mikkilineni, L., Sidana, S., Weng, W., Frank, M., Dahiya, S., Smith, M., Chaudhari, A., Miklos, D. B., Boutin, et al
ELSEVIER SCIENCE INC.2026
 - **Post-transplant cyclophosphamide vs tacrolimus/methotrexate: Improved GRFS, reduced NRM, and less severe GVHD in myeloablative HLA-matched allogeneic transplantation**
Molina, A., Bubb, Q., Yee, R., Arai, S., Bharadwaj, S., Dahiya, S., Elmariah, H., Frank, M., Hosoya, H., Johnston, L., Meyer, E., Mikkilineni, L., Lowsky, et al
ELSEVIER.2025: 2494-2495
 - **Double-dose axicabtagene ciloleucl (Axi-Cel-2) as second-line therapy for high-risk relapsed or refractory large B-cell lymphoma (rLBCL): Interim results from a Phase 1b study**
Lee, D., Rodrigues, K., Rana, M., Kozy, K., Salazar, S., Jensen, A., Desai, M., Mallampet, J., Lohman, C., Huang, Y., Kang, X., Tian, F., Mutter, et al
ELSEVIER.2025: 671-672
 - **Pre-treatment CD19 antigen density and multi-antigen profiling by calibrated quantitative flow cytometry correlates with CAR T efficacy in LBCL**
Spiegel, J., Oak, J., Rana, M., Jensen, A., Lee, D., Nguyen-Mau, S., Kong, K., Bornheimer, S., Mikkilineni, L., Muffly, L., Sidana, S., Weng, W., Bharadwaj, et al
ELSEVIER.2025: 5882-5883
 - **Allogeneic HSC and regulatory T cell (Orca-T) engineered cell therapy following reduced intensity conditioning: Results of a single center Phase 1 study**
Villar-Prados, A., Kim, P., Sutherland, K., Negrin, R., Arai, S., Frank, M., Johnston, L., Lowsky, R., Miklos, D., Muffly, L., Dahiya, S., Rezvani, A., Sidana, et al
ELSEVIER.2025: 111-112
 - **Allogeneic hematopoietic cell transplantation in acute myeloid leukemia not in complete remission: outcomes and prognostic factors in a contemporary cohort.** *Blood cancer journal*

- Elias, S., Brown, S., Egini, O., Walji, M., Homsy, S., Velayati, A., Devlin, S., Ponce, D. M., Kennedy, V., Bharadwaj, S., Shiraz, P., Jakubowski, A. A., Papadopoulos, et al
2025; 15 (1): 208
- **CD22-directed CAR-T cells induce complete remissions in high-risk follicular and Mantle Cell Lymphoma with limited neurotoxicity**
Srinagesh, H., Kramer, A., Hamilton, M., Su, Y., Kozy, K., Jackson, L., Brown, A., Denoble, K., Mavroukakis, S., Lohman, C., Cunanan, K., Agarwal, N., Bharadwaj, et al
ELSEVIER.2025: 4159-4160
 - **Redefining post-CD19 CAR T-cell surveillance with ctDNA: Real-world insights from post- axi-cel and liso-cel therapy**
Ananth, S., Mallampet, J., Chang, B., Agarwal, N., Kong, K., Sahaf, B., Serrato, J., Kirsch, I., Jacob, A., Simmons, H., Lee, L., Mackall, C., Weng, et al
ELSEVIER.2025: 941-942
 - **Validated PET-CT metabolic tumor volume threshold identifies high-risk relapsed/refractory LBCL and predicts 12-month toxicity-free progression-free survival Post-CAR-T therapy**
Rana, M., Ghalehsari, N., Jensen, A., Lee, D., Park, N., Goyal, A., Hashmi, A., Wang, W., Heng, E., Velayati, A., Dhapola, G., Huang, Y., Sahaf, et al
ELSEVIER.2025: 397-398
 - **Patients with TP53-mutated AML/MDS without complex or monosomal karyotype can achieve durable survival benefits with allogeneic HCT**
Jeyakumar, N., Torres, N., Godbole, S., Yamamoto, F., Zhang, B., Arai, S., Bharadwaj, S., Dahiya, S., Elmariah, H., Frank, M., Hosoya, H., Johnston, L., Meyer, et al
ELSEVIER.2025: 2525-2526
 - **Superior efficacy and persistence of Orca-T-allogeneic CAR19/22 versus autologous CAR19/22 in high-risk adult B-ALL**
Molina, A., Shiraz, P., Kanegai, A., Fraser, A., Kordek, D., Wagner, C., Srinagesh, H., Danley, L., Ramakrishnan, A., Daghigh, H., Huang, Y., Dhapola, G., Siddiqui, et al
ELSEVIER.2025: 514-515
 - **From response to rupture: Evaluating GI perforation after CD19 CAR-T in LBCL**
Velayati, A., Rana, M., Jensen, A., Lee, D., Ghalehsari, N., Goyal, A., Latchford, T., Wang, W., Heng, E., Weng, W., Smith, M., Bharadwaj, S., Frank, et al
ELSEVIER.2025: 2771-2772
 - **Non-response to bridging therapy prior to CAR-T is associated with increased toxicity and adverse outcomes in Relapsed/Refractory multiple myeloma (RRMM)**
Rana, M., Jensen, A., Velayati, A., Hovanky, V., Muffly, L., Sahaf, B., Iberri, D., Liedtke, M., Bharadwaj, S., Kennedy, V., Arai, S., Shiraz, P., Weng, et al
ELSEVIER.2025: 4586-4587
 - **Optimizing post-transplantation cell therapies to enhance graft-versus-leukemia effects in hematological malignancies. *Current opinion in immunology***
Minnie, S. A., Berrien-Elliott, M. M., Smith, M., Biernacki, M. A., Bleakley, M.
2025; 97: 102675
 - **Infectious Complications Following CD30 Chimeric Antigen Receptor T-cell Therapy in Adults. *Open forum infectious diseases***
Cao, F., Xiu, Y., Mohnasky, M., Serody, J. S., Armistead, P., Dotti, G., Smith, M., Huggins, J., Messina, J., Ramachandran, B., Saullo, J., Stromberg, J., Saha, et al
2025; 12 (9): ofaf541
 - **Kitlo hematopoietic stem cells exhibit distinct lymphoid-primed chromatin landscapes that enhance thymic reconstitution. *Nature communications***
Elias, H. K., Mitra, S., da Silva, M. B., Rajagopalan, A., Gipson, B., Lee, N., Kousa, A. I., Ali, M. A., Grassmann, S., Raghuraman, R., Zhang, X. C., DeWolf, S., Smith, et al
2025; 16 (1): 6170
 - **Infection after CD19 chimeric antigen receptor T cell therapy for large B cell lymphoma: Real-world analysis from CIBMTR. *Blood advances***
Wudhikarn, K., Herr, M. M., Chen, M., Martens, M. J., Baird, J. H., Gowda, L., Rangarajan, H. G., Abid, M. B., Kharfan-Dabaja, M. A., Williams, K. M., Ganguly, S., Young, J. H., Sharma, et al
2025

- **Fatal Recurrence of IEC-HS Following Autologous Stem Cell Boost in Patients Receiving BCMA CAR-T Cell Therapy.** *Blood advances*
Ananth, S., Torres, N. E., Sahaf, B., Mikkilineni, L., Fernandez-Pol, S., Salmi, D., Negrin, R. S., Shiraz, P., Smith, M., Bharadwaj, S., Weng, W. K., Kennedy, V. E., Dahiya, et al
2025
- **Autologous Transplant or CAR-T as Consolidation Options in MYC Rearranged Large B-Cell Lymphoma Patients in Remission After Salvage Treatments.** *American journal of hematology*
Furqan, F., Ahn, K. W., Kaur, M., Patel, J., Ansell, S., Awan, F. T., Baird, J., Bezerra, E., Farooq, U., Fung, H., Khurana, A., Lekakis, L., Lutfi, et al
2025
- **Lisocabtagene Maraleucel for Richter's Transformation-A Case Series.** *EJHaem*
Smith, C. J., Goyal, A., Smith, B. R., Lee, D., Jensen, A., Alexander, J., Smith, M., Frank, M., Dahiya, S., Miklos, D., Bharadwaj, S.
2025; 6 (2): e270011
- **Tackling the next decade of cancer research.** *Trends in cancer*
Ali, R., Jenkins, B., Karthaus, W., Lipkova, J., Misale, S., Puschhof, J., Smith, M., Vardhana, S., Zhou, X.
2025
- **Epigenetic enhancement of adoptive T cell immunotherapy.** *Cancer cell*
Dai, Z., Smith, M.
2025; 43 (3): 340-342
- **Effects of an initial anti-CD19 CAR T-cell therapy on subsequent anti-CD22 CAR T-cell manufacturing and clinical outcomes in patients with r/r LBCL.** *Cancer discovery*
Su, Y. J., Kramer, A. M., Hamilton, M. P., Agarwal, N., Srinagesh, H. K., Baird, J. H., Sahaf, B., Kuo, A., Ehlinger, Z. J., Desai, M. H., Rietberg, S. P., Tunuguntla, R., Patel, et al
2025
- **A 17-Year Experience of a Large Dedicated Fellowship in Blood and Marrow Transplantation and Cellular Therapy: A Blueprint for Modern Day Training Program.** *Journal of cancer education : the official journal of the American Association for Cancer Education*
Bharadwaj, S., Lowsky, R., Mikkilineni, L., Smith, M., Weng, W. K.
2024
- **Indolent CD8+CAR T-Cell Lymphoma of the Gastrointestinal Tract after Ciltacabtagene Autoleucel Therapy for Relapsed/Refractory Multiple Myeloma**
Hosoya, H., Fernandez-Pol, S., Gubatan, J., Ehlinger, Z., Lohman, C., Torres, A., Najidh, S., Kwang, A., Duran, G., Wright, C., Kennedy, V. E., Bharadwaj, S., Smith, et al
ELSEVIER.2024: 4846-4847
- **CD22-Directed CAR T-Cell Therapy Achieves Complete Remission in CD19-Directed CAR T-Cell Refractory Follicular and Mantle Cell Lymphoma**
Kramer, A., Srinagesh, H., Su, Y., Hamilton, M. P., Levine, K., Migliore, E., Denoble, K., Brown, A. K., Cunanan, K., Agarwal, N., Lohman, C., Mavroukakis, S., Bharadwaj, et al
ELSEVIER.2024: 2064-2066
- **Point-of-Care Bispectral Electroencephalogram (BSEEG) As a New Tool in Detecting Immune Effector Cell Associated Neurotoxicity (ICANS) in Patients Treated with Chimeric Antigen Receptor T-Cell (CAR-T)**
Homsy, S., Seki, T., Nguyen, H., Shimura, A., Gorantla, N., Phuong, N., Ghalehsari, N., Velayati, A., Jeyakumar, N., Hamilton, M. P., Kennedy, V. E., Mikkilineni, L., Bharadwaj, et al
ELSEVIER.2024: 7134-7135
- **Safe and Effective Combination of Donor-Derived, Allogeneic CD19/CD22-CAR T Cells with Myeloablative Graft-Engineered Allo-HCT for High-Risk B-ALL**
Muffy, L., Ananth, S., Danley, L., Wagner, C., Kordek, D., Denoble, K., Fraser, A., Egeler, E., Molina, A., Ehlinger, Z., Desai, M., Daghigh, H., Tunuguntla, et al
ELSEVIER.2024: 680
- **Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy in Octogenarian Patients (Aged > 80) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)**
Lee, D., Bharadwaj, S., Rana, M. S., Jensen, A., Wang, W., Ghalehsari, N., Sahaf, B., Mallampet, J., Elkordy, S., Latchford, T., Arai, S., Johnston, L., Hosoya, et al

ELSEVIER.2024: 386-387

- **Anti-BCMA CAR T-Cell Expansion and Its Association with Response and Toxicity in Multiple Myeloma**
Hosoya, H., Jensen, A., Hovanky, V., Homsy, S., Cancilla, J. E., Patil, S., Kennedy, V. E., Bharadwaj, S., Smith, M., Shiraz, P., Frank, M. J., Dahiya, S., Arai, et al
ELSEVIER.2024: 2006-2007
- **CD22-Directed CAR T-Cell Therapy for Large B-Cell Lymphomas Progressing after CD19-Directed CAR T-Cell Therapy: Continued Durable Remissions at 3-Year Follow-up**
Kramer, A., Baird, J. H., Srinagesh, H., Egeler, E., Levine, K., Brown, A. K., Mavroukakis, S., Cunanan, K., Su, Y., Agarwal, N., Hamilton, M. P., Bharadwaj, S., Arai, et al
ELSEVIER.2024: 70-71
- **Single Institution Analysis of Lymphoma Treatment Related Post-CAR Myeloid Neoplasms**
Hamilton, M., Phillips, N., Lee, D., Ehlinger, Z., Kramer, A., Srinagesh, H., Good, Z., Kang, X., Olsen, M., Liu, C., Tian, F., Sworder, B. J., Hosoya, et al
ELSEVIER.2024: 96-97
- **Infectious Complications Following CD30 Chimeric Antigen Receptor T-Cell Therapy in Adults.** *medRxiv : the preprint server for health sciences*
Cao, F., Xiu, Y., Mohnasky, M., Serody, J. S., Armistead, P., Dotti, G., Smith, M., Huggins, J., Messina, J., Ramachandran, B., Saullo, J., Stromberg, J., Saha, et al
2024
- **CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study.** *Lancet (London, England)*
Frank, M. J., Baird, J. H., Kramer, A. M., Srinagesh, H. K., Patel, S., Brown, A. K., Oak, J. S., Younes, S. F., Natkunam, Y., Hamilton, M. P., Su, Y. J., Agarwal, N., Chinnasamy, et al
2024
- **A Phase 1 Clinical Trial of NKTR-255 with CD19-22 CAR-T Cell Therapy for Refractory B-cell Acute Lymphoblastic Leukemia.** *Blood*
Srinagesh, H. K., Jackson, C., Shiraz, P., Jeyakumar, N., Hamilton, M. P., Egeler, E., Mavroukakis, S., Kuo, A., Cancilla, J., Sahaf, B., Agarwal, N., Kanegai, A. M., Kramer, et al
2024
- **Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphoma.** *Journal for immunotherapy of cancer*
Bharadwaj, S., Lau, E., Hamilton, M. P., Goyal, A., Srinagesh, H., Jensen, A., Lee, D., Mallampet, J., Elkordy, S., Syal, S., Patil, S., Latchford, T., Sahaf, et al
2024; 12 (7)
- **CAR T cell Toxicities: Bedside to Bench - How Novel Toxicities Inform Laboratory Investigations.** *Blood advances*
Perna, F., Parekh, S., Diorio, C., Smith, M., Subklewe, M., Mehta, R., Locke, F. L., Shah, N. N.
2024
- **Recruitment and Retention of Hematopoietic Cell Transplantation and Cellular Therapy Physicians: A Report from the ASTCT Talent Acquisition Task Force.** *Transplantation and cellular therapy*
Sharma, A., Czechowicz, A., Mavers, M., Chao, N., DiPersio, J., Reddy, P., Perales, M. A., Smith, M.
2024
- **An Assessment of CAR-T Cell Therapy Utilization among Racial and Ethnic Minority Patients.** *NEJM evidence*
Hill, L. C., Smith, M.
2024; 3 (4): EVIDe2400022
- **CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity.** *Blood advances*
Hamilton, M. P., Craig, E., Gentile Sanchez, C., Mina, A., Tamaresis, J., Kirmani, N., Ehlinger, Z., Syal, S., Good, Z., Sworder, B., Schroers-Martin, J., Lu, Y., Muffly, et al
2024
- **Altered microbial bile acid metabolism exacerbates T cell-driven inflammation during graft-versus-host disease.** *Nature microbiology*
Lindner, S., Miltiados, O., Ramos, R. J., Paredes, J., Kousa, A. I., Dai, A., Fei, T., Lauder, E., Frame, J., Waters, N. R., Sadeghi, K., Armijo, G. K., Ghale, et al

2024

- **Clinical Features of Neurotoxicity Following CD19 CAR T-cell Therapy in Mantle Cell Lymphoma.** *Blood advances*
Nie, E. H., Su, Y. J., Baird, J. H., Agarwal, N., Bharadwaj, S., Weng, W. K., Smith, M., Dahiya, S., Han, M. H., Dunn, J. E., Kipp, L. B., Miklos, D. B., Scott, et al
2024
- **Microbes matter in pediatric allo-HSCT.** *Blood*
Smith, M., Markey, K. A.
2023; 142 (16): 1335-1337
- **How I Treat Refractory CRS and ICANS Following CAR T-cell Therapy.** *Blood*
Jain, M. D., Smith, M., Shah, N. N.
2023
- **Harnessing ADR T cells to enhance allo-HCT.** *Blood*
Smith, M.
2023; 141 (10): 1101-1102
- **Author Correction: Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy.** *Nature medicine*
Smith, M., Dai, A., Ghilardi, G., Amelsberg, K. V., Devlin, S. M., Pajarillo, R., Slingerland, J. B., Beghi, S., Herrera, P. S., Giardina, P., Clurman, A., Dwomoh, E., Armijo, et al
2022
- **Burnout in U.S. hematologists and oncologists: impact of compensation models and advanced practice provider support.** *Blood advances*
Lee, A. I., Masselink, L. E., De Castro, L. M., Marshall, A. L., Connell, N. T., Dent, G. A., Fritz, J., Homer, M. R., Lucas, T. L., Naik, R. P., Nelson, M., O'Connell, C. L., Rajasekhar, et al
2022
- **Custom CARs: Leveraging the Adaptability of Allogeneic CAR Therapies to Address Current Challenges in Relapsed/Refractory DLBCL.** *Frontiers in immunology*
Jeyakumar, N., Smith, M.
2022; 13: 887866
- **The Composition of the Intestinal Microbiota Correlates with Response and Toxicity after CAR T cell Immunotherapy in Patients with B-cell Malignancies**
Smith, M.
Nature Medicine .
2021
- **A Question of Beneficence: Comorbidity Assessment to Ascertain Potential Benefit of CD19 Chimeric Antigen Receptor T Cells for Patients with Diffuse Large B Cell Lymphoma** *TRANSPLANTATION AND CELLULAR THERAPY*
Smith, M.
2021; 27 (1): 2-3
- **Relapse after allogeneic stem cell transplantation of acute myeloid leukemia and myelodysplastic syndrome and importance of second cellular therapy.**
Smith, M.
Transplantation and Cellular Therapy.
2021
- **Alloreactive T cells deficient of the short-chain fatty acid receptor GPR109a induce less graft-versus-host disease**
Smith, M.
Blood.
2021
- **The gut microbiota is associated with immune cell dynamics in humans** *NATURE*
Schluter, J., Peled, J. U., Taylor, B. P., Markey, K. A., Smith, M., Taur, Y., Niehus, R., Staffas, A., Dai, A., Fontana, E., Amoretti, L. A., Wright, R. J., Morjaria, et al
2020; 588 (7837): 303-307

- **Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies** *BLOOD ADVANCES*
Jain, T., Knezevic, A., Pennisi, M., Chen, Y., Ruiz, J. D., Purdon, T. J., Devlin, S. M., Smith, M., Shah, G. L., Halton, E., Diamonte, C., Scordo, M., Sauter, et al
2020; 4 (15): 3776-3787
- **Impaired mitochondrial oxidative phosphorylation limits the self-renewal of T cells exposed to persistent antigen.** *Nature immunology*
Vardhana, S. A., Hwee, M. A., Berisa, M., Wells, D. K., Yost, K. E., King, B., Smith, M., Herrera, P. S., Chang, H. Y., Satpathy, A. T., van den Brink, M. R., Cross, J. R., Thompson, et al
2020
- **Associations between hematology/oncology fellows' training and mentorship experiences and hematology-only career plans** *BLOOD ADVANCES*
Masselink, L. E., Erikson, C. E., Connell, N. T., De Castro, L. M., Dent, G. A., Marshall, A. L., Naik, R. P., Nelson, M., O'Connell, C. L., Rajasekhar, A., Sharma, D., Smith, M., Lee, et al
2019; 3 (21): 3278-3286
- **Standard Antithymocyte Globulin Dosing Results in Poorer Outcomes in Overexposed Patients after Ex Vivo CD34(+) Selected Allogeneic Hematopoietic Cell Transplantation** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Scordo, M., Bhatt, V., Hilden, P., Smith, M., Thoren, K., Cho, C., Shah, G. L., Maloy, M. A., Papadopoulos, E. B., Jakubowski, A. A., Avecilla, S. T., O'Reilly, R. J., Castro-Malaspina, et al
2019; 25 (8): 1526-1535
- **Trial Watch: Toll-like receptor agonists in cancer immunotherapy** *ONCOIMMUNOLOGY*
Smith, M., Garcia-Martinez, E., Pitter, M. R., Fucikova, J., Spisek, R., Zitvogel, L., Kroemer, G., Galluzzi, L.
2018; 7 (12): e1526250
- **Multicenter Microbiota Analysis Indicates That Pre-HCT Microbiota Injury Is Prevalent across Geography and Predicts Poor Overall Survival**
Peled, J. U., Gomes, A. L. C., Stein-Thoeringer, C. K., Slingerland, J. B., Slingerland, A. E., Weber, D., Markey, K. A., Smith, M., Ponce, D., Clurman, A., Sung, A. D., Hashimoto, D., Maloy, et al
AMER SOC HEMATOLOGY.2018
- **Intestinal Microbiota Composition Prior to CAR T Cell Infusion Correlates with Efficacy and Toxicity**
Smith, M., Littmann, E. R., Slingerland, J. B., Clurman, A., Slingerland, A. E., Taur, Y., Schluter, J., Park, J. H., O'Cearbhaill, R., Mailankody, S., Smith, E. L., Palomba, M., Yeku, et al
AMER SOC HEMATOLOGY.2018
- **Posttransplant chimeric antigen receptor therapy** *BLOOD*
Smith, M., Zakrzewski, J., James, S., Sadelain, M.
2018; 131 (10): 1045-1052
- **Empiric Anti-Thymocyte Globulin (ATG) Dosing in Ex Vivo CD34-Selected Myeloablative Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) May Result in ATG Overexposure That Negatively Affects Outcomes**
Scordo, M., Bhatt, V., Smith, M., Thoren, K., Hilden, P., Cho, C., Shah, G. L., Maloy, M., Papadopoulos, E. B., Jakubowski, A. A., O'Reilly, R. J., Castro-Malaspina, H., Tamari, et al
ELSEVIER SCIENCE INC.2018: S71-S72
- **Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy** *ONCOIMMUNOLOGY*
Garcia-Martinez, E., Smith, M., Buque, A., Aranda, F., Ayala de la Pena, F., Ivars, A., Sanchez Canovas, M., Vicente Conesa, M., Fucikova, J., Spisek, R., Zitvogel, L., Kroemer, G., Galluzzi, et al
2018; 7 (6): e1433982
- **Allogeneic Hematopoietic Cell Transplantation for Adult T Cell Acute Lymphoblastic Leukemia.** *Biology of blood and marrow transplantation*
Hamilton, B. K., Rybicki, L., Abounader, D., Adekola, K., Advani, A., Aldoss, I., Bachanova, V., Bashey, A., Brown, S., DeLima, M., Devine, S., Flowers, C. R., Ganguly, et al
2017
- **Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis** *LEUKEMIA*
Landau, H., Smith, M., Landry, C., Chou, J. F., Devlin, S. M., Hassoun, H., Bello, C., Giralt, S., Comenzo, R. L.
2017; 31 (1): 136-142

- **Tumor immunology and cancer immunotherapy: summary of the 2014 SITC primer** *JOURNAL FOR IMMUNOTHERAPY OF CANCER*
Page, D. B., Bourla, A., Daniyan, A., Naidoo, J., Smith, E., Smith, M., Friedman, C., Khalil, D. N., Funt, S., Shoushtari, A. N., Overwijk, W. W., Sharma, P., Callahan, et al
2015; 3
- **Increased Bone Marrow Plasma Cells at Diagnosis Predicts Overall Mortality in AL Amyloidosis Patients Undergoing Risk-Adapted Stem Cell Transplant**
Landry, C. A., Smith, M., Chou, J. F., Devlin, S. M., Hassoun, H., Bello, C., Landgren, O., Giralt, S., Comenzo, R. L., Landau, H.
AMER SOC HEMATOLOGY.2014
- **Racial Differences in the Presentation and Outcomes of Chronic Lymphocytic Leukemia and Variants in the United States** *CLINICAL LYMPHOMA MYELOMA & LEUKEMIA*
Shenoy, P. J., Malik, N., Sinha, R., Nooka, A., Nastoupil, L. J., Smith, M., Flowers, C. R.
2011; 11 (6): 498-506
- **Both naive and memory T cells exert alloreactivity across HLA barriers**
Smith, M.
Biology of Blood and Marrow Transplantation.
2011
- **Clinical, Molecular, and Environmental Risk Factors for Hodgkin Lymphoma**
Smith, M.
Advances in Hematology.
2011